Brief: Aurinia Pharmaceuticals Says FDA Has Approved A Label Update For Lupkynis

Aurinia Pharmaceuticals

30/04/2024 11:13

April 30 (Reuters) - Aurinia Pharmaceuticals Inc
 AUPH.O :
    * AURINIA PHARMACEUTICALS INC: FDA HAS APPROVED A LABEL
UPDATE FOR
LUPKYNIS
    * AURINIA PHARMACEUTICALS INC: SAFETY PROFILE REMAINS
UNCHANGED
AND IS ALIGNED WITH SAFETY FINDINGS IN AURORA CLINICAL PROGRAM
    * AURINIA PHARMACEUTICALS INC: MONTHLY KIDNEY FUNCTION
ASSESSMENT
NO LONGER REQUIRED AFTER FIRST YEAR OF TREATMENT
    * AURINIA PHARMACEUTICALS INC: NEW DATA SHOWING SUSTAINED
COMPLETE
RENAL RESPONSE WITH LUPKYNIS THROUGH THREE YEARS
    * AURINIA PHARMACEUTICALS INC: LABEL NOW INCLUDES THREE-YEAR
DATA
FROM AURORA 2 DOUBLE-BLIND, PLACEBO-CONTROLLED EXTENSION STUDY

Source text for Eikon:  ID:nBw43h3Lza 
Further company coverage:  AUPH.O 

 (Reuters.Briefs@thomsonreuters.com)